Prnewswire Slate Bio Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies
Financing will support development of novel IL-2 treatments for various diseases
CHARLOTTESVILLE, Va., Jan. 19, 2021 /PRNewswire/ Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others. Slate is a pre-clinical biotechnology company developing paradigm shifting IL-2 compounds based on research conducted at the University of Virginia School of Medicine. IL233, Slate s lead candidate, is a first in class drug that induces persistent remission in animal models of autoimmune and inflammatory diseases. ....

United Kingdom , Kostenloser Wertpapierhandel , Kyp Sirinakis , Andrewj Krouse , Andrew Krouse , Bob Creeden , Seed Fund , Prnewswire Slate Bio Inc , University Of Virginia School Medicine , Biolife Fund , Licensing Ventures Group Seed Fund , Pharmadirections Inc , University Of Virginia , Innovative Technology , Slate Bio Inc , Ventures Group Seed Fund , Life Fund , Virginia School , Epidarex Capital , Chief Executive Officer , While Fc Fusions , Managing Partner , Managing Director , Slate Board , Slate Bio , ஒன்றுபட்டது கிஂக்டம் ,